First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

Yuankai Shi; Sheng Hou; Yi Ba; Zishu Wang; Ying Cheng; Jiansi Chen; Jianping Xiong; Da Jiang; Yigui Chen; Qi Li; Yuxian Bai; Wei Li; Kangsheng Gu; Weijian Guo; Jingdong He; Jianguo Sun; Enxiao Li; Zhendong Zheng; Junye Wang; Yunpeng Liu; Liangjun Zhu

doi:10.1038/s41392-025-02229-4

First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Sheng Hou(Second Military Medical University), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Zishu Wang(Bengbu Medical College), Ying Cheng(Jilin Province Tumor Hospital), Jiansi Chen(Tumor Hospital of Guangxi Medical University), Jianping Xiong(Nanchang University), Da Jiang(Hebei Medical University), Yigui Chen(Fujian Medical University), Qi Li(Shanghai Jiao Tong University), Yuxian Bai(Harbin Medical University), Wei Li(Jilin University), Kangsheng Gu(Anhui Medical University), Weijian Guo(Shanghai Medical College of Fudan University), Jingdong He(Huaian First People’s Hospital), Jianguo Sun(Army Medical University), Enxiao Li(First Affiliated Hospital of Xi'an Jiaotong University), Zhendong Zheng(General Hospital of Shenyang Military Region), Junye Wang(Affiliated Hospital of Jining Medical University), Yunpeng Liu(Shenyang Institute of Automation), Liangjun Zhu(Jiangsu Cancer Hospital)

Signal Transduction and Targeted Therapy

May 6, 2025

10.1038/s41392-025-02229-4

Cited by 8

|New England Journal of Medicine|2018|3.7k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.4k

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2017|1.2k

Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA

|Cell Research|2011|1.2k

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

|The Lancet Oncology|2016|1.2k

First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

Related Papers